SPY317.59+3.21 1.02%
DIA260.82+3.58 1.39%
IXIC10,617.44+69.69 0.66%

Goldman Sachs Downgrades Passage Bio to Neutral, Announces $28 Price Target

Goldman Sachs analyst Salveen Richter downgrades Passage Bio (NASDAQ:PASG) from Buy to Neutral and announces $28 price target.

Benzinga · -
Goldman Sachs analyst Salveen Richter downgrades Passage Bio (NASDAQ: PASG) from Buy to Neutral and announces $28 price target.